BETANSEBeta Drugs LimitedMediumNeutral
Announced Sat, 25 Apr · 13:59 IST

Beta Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on April 25, 2026.

Listed Co AcquisitionStrategic Transactions View source PDF

BETA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-3.7%1-day move
₹1343.20
prior close
₹1336.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.6-0.1-0.1-0.4-3.7-3.0-1.7-1.0-1.0+0.5-12.1+7.2+61.4+65.9
Up moveDown movePending
AI summary

Beta Drugs Limited's board approved allotment of 2,83,668 equity shares at INR 1,712.49 per share (including premium of INR 1,702.49) to fund the acquisition of Nivian Lifesciences Private Limited. The shares have a face value of INR 10 each. The board meeting was held on April 25, 2026 from 11:00 AM to 01:55 PM. This is a share-based consideration for the acquisition.

Likely market impact

The acquisition of Nivian Lifesciences through equity issuance will dilute existing shareholders by approximately 2.84 lakh new shares. The deal may expand Beta Drugs' product portfolio or market presence in the pharmaceutical sector.